1. Home
  2. ATRA vs HXHX Comparison

ATRA vs HXHX Comparison

Compare ATRA & HXHX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ATRA
  • HXHX
  • Stock Information
  • Founded
  • ATRA 2012
  • HXHX 2003
  • Country
  • ATRA United States
  • HXHX China
  • Employees
  • ATRA N/A
  • HXHX N/A
  • Industry
  • ATRA Biotechnology: Biological Products (No Diagnostic Substances)
  • HXHX Trucking Freight/Courier Services
  • Sector
  • ATRA Health Care
  • HXHX Industrials
  • Exchange
  • ATRA Nasdaq
  • HXHX Nasdaq
  • Market Cap
  • ATRA 40.1M
  • HXHX 36.9M
  • IPO Year
  • ATRA 2014
  • HXHX 2025
  • Fundamental
  • Price
  • ATRA $8.00
  • HXHX $1.81
  • Analyst Decision
  • ATRA Buy
  • HXHX
  • Analyst Count
  • ATRA 5
  • HXHX 0
  • Target Price
  • ATRA $17.75
  • HXHX N/A
  • AVG Volume (30 Days)
  • ATRA 78.7K
  • HXHX 171.6K
  • Earning Date
  • ATRA 05-15-2025
  • HXHX 01-01-0001
  • Dividend Yield
  • ATRA N/A
  • HXHX N/A
  • EPS Growth
  • ATRA N/A
  • HXHX N/A
  • EPS
  • ATRA N/A
  • HXHX 0.26
  • Revenue
  • ATRA $199,732,000.00
  • HXHX $25,571,810.00
  • Revenue This Year
  • ATRA N/A
  • HXHX N/A
  • Revenue Next Year
  • ATRA N/A
  • HXHX N/A
  • P/E Ratio
  • ATRA N/A
  • HXHX $6.31
  • Revenue Growth
  • ATRA 475.53
  • HXHX N/A
  • 52 Week Low
  • ATRA $5.01
  • HXHX $1.29
  • 52 Week High
  • ATRA $18.71
  • HXHX $6.29
  • Technical
  • Relative Strength Index (RSI)
  • ATRA 61.05
  • HXHX N/A
  • Support Level
  • ATRA $7.44
  • HXHX N/A
  • Resistance Level
  • ATRA $8.10
  • HXHX N/A
  • Average True Range (ATR)
  • ATRA 0.53
  • HXHX 0.00
  • MACD
  • ATRA 0.09
  • HXHX 0.00
  • Stochastic Oscillator
  • ATRA 92.28
  • HXHX 0.00

About ATRA Atara Biotherapeutics Inc.

Atara Biotherapeutics Inc operates in the United States healthcare sector. It focuses on developing transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune diseases. It operates and manages business as one operating and reportable segment which is the business of developing therapeutics. The company's product candidates comprise Tab-cel, ATA188, and ATA3219 (CAR T Platform).

Share on Social Networks: